Department of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, HWCRC - 4th Floor, 4100 John R, Detroit, MI 48201, USA.
Department of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, HWCRC - 4th Floor, 4100 John R, Detroit, MI 48201, USA.
Infect Dis Clin North Am. 2020 Jun;34(2):245-256. doi: 10.1016/j.idc.2020.02.008.
Tyrosine kinase inhibitors represent the standard of care for several diseases and drug targets in hematologic malignancies. Infectious complications vary by disease status and prior therapy, but overall incidence of infections generally is low. In chronic diseases, such as chronic myeloid leukemia and chronic lymphocytic leukemia, patients can remain on tyrosine kinase inhibitor therapy for many years, with few infectious complications from therapy. Bruton tyrosine kinase inhibitors overall are well tolerated in lymphoproliferative disorders, with long-term follow-up of many years in patients with chronic lymphocytic leukemia. Although opportunistic infections have been reported, they are uncommon and routine prophylaxis is not recommended.
酪氨酸激酶抑制剂是几种血液系统恶性肿瘤疾病和药物靶点的标准治疗方法。感染并发症因疾病状态和既往治疗而异，但总体感染发生率通常较低。在慢性疾病（如慢性髓性白血病和慢性淋巴细胞白血病）中，患者可以接受多年的酪氨酸激酶抑制剂治疗，很少有因治疗引起的感染并发症。布鲁顿酪氨酸激酶抑制剂在淋巴增殖性疾病中总体耐受性良好，慢性淋巴细胞白血病患者的长期随访时间长达数年。虽然有报道称出现了机会性感染，但并不常见，也不建议常规预防。
